Clinical Value of Semi-quantitative Parameters in Ga-DOTANOC PET/CT in Treatment and Diagnostics of Cranial Meningioma in a Single-center Retrospective Analysis

Overview

Journal EJNMMI Rep

Publisher Springer Nature

Date 2024 May 15

PMID 38748290

Authors

Friedrich Weitzer

Susanne Stanzel

Elisabeth Plhak

Reingard Maria Aigner

Affiliations

Soon will be listed here.

Abstract

Background: The value of somatostatin-analogon PET tracers in theranostics in cranial meningioma has been demonstrated in several studies; however, the value of semi-quantitative parameters for therapy and patient outcome is still unclear.

Methods: A retrospective study was performed comparing measured semi-quantitative Ga-DOTANOC PET/CT parameters (maximum standardized uptake value = SUVmax, mean standardized uptake value = SUVmean, and metabolic tumor volume = MTV) and calculated ratios (SUVmax tumor to pituitary gland and SUVmax tumor to superior sinus sagittalis), versus the WHO grades and overall outcome. Patients with histological confirmed meningioma or high probability for meningioma in the previous cranial MRI were eligible.

Results: Thirty-two patients from January 2018 to February 2023 were retrospectively included. The WHO grade I meningioma was confirmed in 17 patients, the WHO grade II in five patients, and the WHO grade III in two patients, while in eight patients, diagnosis was solely based on MRI and Ga-DOTANOC PET/CT findings. In 12 cases, stable disease was present, in 15 cases, radiation therapy was chosen, in three cases, neurosurgery was preferred, while in two cases, palliative care was chosen. Median SUVmax values increased with the WHO grade (15.84, 17.22, and 28.4, p = 0.134, Kruskal-Wallis test), and no statistically significant difference was present for MTV, SUVmax, and calculated ratios.

Conclusion: Increased SUVmax values in the tumor in Ga-DOTANOC PET/CT are associated with higher WHO grade, although further studies including larger patient collectives are needed to solidify this hypothesis.

References

Goldbrunner R, Stavrinou P, Jenkinson M, Sahm F, Mawrin C, Weber D . EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol. 2021; 23(11):1821-1834. PMC: 8563316. DOI: 10.1093/neuonc/noab150. View

Filippi L, Palumbo I, Bagni O, Schillaci O, Aristei C, Palumbo B . Somatostatin Receptor Targeted PET-Imaging for Diagnosis, Radiotherapy Planning and Theranostics of Meningiomas: A Systematic Review of the Literature. Diagnostics (Basel). 2022; 12(7). PMC: 9321668. DOI: 10.3390/diagnostics12071666. View

Marosi C, Hassler M, Roessler K, Reni M, Sant M, Mazza E . Meningioma. Crit Rev Oncol Hematol. 2008; 67(2):153-71. DOI: 10.1016/j.critrevonc.2008.01.010. View

Hope T, Allen-Auerbach M, Bodei L, Calais J, Dahlbom M, Dunnwald L . SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors. J Nucl Med. 2023; 64(2):204-210. DOI: 10.2967/jnumed.122.264860. View

Kriwanek F, Ulbrich L, Lechner W, Lutgendorf-Caucig C, Konrad S, Waldstein C . Impact of SSTR PET on Inter-Observer Variability of Target Delineation of Meningioma and the Possibility of Using Threshold-Based Segmentations in Radiation Oncology. Cancers (Basel). 2022; 14(18). PMC: 9497299. DOI: 10.3390/cancers14184435. View

Maggio I, Franceschi E, Tosoni A, Di Nunno V, Gatto L, Lodi R . Meningioma: not always a benign tumor. A review of advances in the treatment of meningiomas. CNS Oncol. 2021; 10(2):CNS72. PMC: 8162186. DOI: 10.2217/cns-2021-0003. View

Salmon E, Bernard Ir C, Hustinx R . Pitfalls and Limitations of PET/CT in Brain Imaging. Semin Nucl Med. 2015; 45(6):541-51. DOI: 10.1053/j.semnuclmed.2015.03.008. View

Aerts J, Ballinger J, Behe M, Decristoforo C, Elsinga P, Faivre-Chauvet A . Guidance on current good radiopharmacy practice for the small-scale preparation of radiopharmaceuticals using automated modules: a European perspective. J Labelled Comp Radiopharm. 2014; 57(10):615-20. DOI: 10.1002/jlcr.3227. View

Bozkurt M, Virgolini I, Balogova S, Beheshti M, Rubello D, Decristoforo C . Guideline for PET/CT imaging of neuroendocrine neoplasms with Ga-DOTA-conjugated somatostatin receptor targeting peptides and F-DOPA. Eur J Nucl Med Mol Imaging. 2017; 44(9):1588-1601. DOI: 10.1007/s00259-017-3728-y. View

10.

Campos Neto G, Junior E, Weltman E, Malheiros S, Ferrari B, Vitor T . Comparative analysis of somatostatin analog uptake between successfully irradiated and non-irradiated meningiomas. Einstein (Sao Paulo). 2022; 20:eAO0104. PMC: 9744426. DOI: 10.31744/einstein_journal/2022AO0104. View

11.

Gillings N, Hjelstuen O, Behe M, Decristoforo C, Elsinga P, Ferrari V . EANM guideline on quality risk management for radiopharmaceuticals. Eur J Nucl Med Mol Imaging. 2022; 49(10):3353-3364. PMC: 9308578. DOI: 10.1007/s00259-022-05738-4. View

12.

Dutour A, Kumar U, Panetta R, Ouafik L, Fina F, Sasi R . Expression of somatostatin receptor subtypes in human brain tumors. Int J Cancer. 1998; 76(5):620-7. DOI: 10.1002/(sici)1097-0215(19980529)76:5<620::aid-ijc2>3.0.co;2-s. View

13.

Milosevic A, Styczen H, Grueneisen J, Li Y, Weber M, Fendler W . Evaluation of [Ga]-DOTATOC PET/MRI in Patients with Meningioma of the Subcranial and Intraorbital Space. J Nucl Med. 2023; 64(8):1185-1190. DOI: 10.2967/jnumed.123.265424. View

14.

Galldiks N, Albert N, Sommerauer M, Grosu A, Ganswindt U, Law I . PET imaging in patients with meningioma-report of the RANO/PET Group. Neuro Oncol. 2017; 19(12):1576-1587. PMC: 5716194. DOI: 10.1093/neuonc/nox112. View

15.

Jacobs F, Thierens H, Piepsz A, Bacher K, Van de Wiele C, Ham H . Optimised tracer-dependent dosage cards to obtain weight-independent effective doses. Eur J Nucl Med Mol Imaging. 2004; 32(5):581-8. DOI: 10.1007/s00259-004-1708-5. View

16.

Vernooij M, Ikram M, Tanghe H, Vincent A, Hofman A, Krestin G . Incidental findings on brain MRI in the general population. N Engl J Med. 2007; 357(18):1821-8. DOI: 10.1056/NEJMoa070972. View

17.

Kim S, Roytman M, Madera G, Magge R, Liechty B, Ramakrishna R . Evaluating diagnostic accuracy and determining optimal diagnostic thresholds of different approaches to [Ga]-DOTATATE PET/MRI analysis in patients with meningioma. Sci Rep. 2022; 12(1):9256. PMC: 9166786. DOI: 10.1038/s41598-022-13467-9. View

18.

Pirisino R, Filippi L, DAgostini A, Bagni O . Management of a Patient With Metastatic Gastrointestinal Neuroendocrine Tumor and Meningioma Submitted to Peptide Receptor Radionuclide Therapy With 177 Lu-DOTATATE. Clin Nucl Med. 2022; 47(11):e692-e695. DOI: 10.1097/RLU.0000000000004307. View